Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 16, 2007

Respironics’ Device Used in Clinical Evaluation Of Interferon Gamma to Treat Idiopathic PF Patients

  • Respironics inked an agreement with The State University of New York (SUNY) and New York University School of Medicine (NYU) to utilize the I-neb Adaptive Aerosol Delivery (AAD®) system for clinical evaluation of aerosolized Interferon Gamma for the treatment of idiopathic pulmonary fibrosis (IPF). The clinical trial will take place over a two-year time period.

    The I-neb device uses Respironics’ AAD technology, which reportedly is an “intelligent” inhalation technology that continually monitors and automatically adapts to an individual patient's breathing pattern to deliver a precise medication dose during the patient's inhalation phase. The result is precise, reproducible dosing of medication to each patient, regardless of his/her breathing pattern, according to the company.

    The I-neb AAD System is Respironics’ third generation AAD System and is smaller, quieter and more portable than earlier product generations, notes a company spokesperson. The device weighs less than eight ounces and can be carried in a purse, pocket or briefcase. The I-neb device also provides audible and visual feedback to the patient informing the patient when the treatment is complete.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »